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Abstract 
Background: Vagus nerve stimulation (VNS) has become the most common non‑pharmacological treatment for 
intractable drug‑resistant epilepsy. However, the contribution of VNS to neurological rehabilitation following stroke has 
not been thoroughly examined. Therefore, we investigated the specific role of acute VNS in the recovery of cognitive 
functioning and the possible mechanisms involved using a cerebral ischemia/reperfusion (I/R) injury model in rats.
Methods: The I/R‑related injury was modeled using occlusion and reperfusion of the middle cerebral artery (MCAO/R) 
in Sprague–Dawley rats. VNS was concurrently applied to the vagus nerve using a stimulation intensity of 1 mA at a 
fixed frequency of 20 Hz with a 0.4‑ms bipolar pulse width. The stimulation duration and inter‑train interval were both 
3 s. Next, Morris water maze and shuttle‑box behavioral experiments were conducted to assess the effects of VNS on 
the recovery of learning, memory, and inhibitory avoidance following I/R injury. Intracerebroventricular injection of 
N‑(2‑chloroethyl)‑N‑ethyl‑2‑bromobenzylamine hydrochloride (DSP‑4), a selective neurotoxin for noradrenergic neurons, 
was used to evaluate the role of norepinephrine (NE) as a mediator of therapeutic effects of VNS on cognitive recovery.
Results: Compared with the MCAO/R group, the VNS+MCAO/R group had improved spatial memory as indicated 
by swimming path lengths and escape latencies in the Morris water maze, and fear memory, as indicated by the 
avoidance conditioned response rate, mean shock duration, and avoidance time in shuttle‑box behavior experi‑
ments. Compared with the VNS+MCAO/R group, the DSP‑4+VNS+MCAO/R group, which had reduced NE levels in 
cortical and hippocampal brain regions, showed a reversal of the VNS‑induced benefits on spatial and fear memory 
performance.
Conclusions: VNS improves spatial and fear memory in a rat model of MCAO/R injury. However, a reduction in NE 
from the administration of DSP‑4 blocks these protective effects, suggesting that NE may contribute to the influence 
exhibited by VNS on memory performance in rats with cerebral I/R‑related injury.
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Background
Stroke is the leading cause of chronic adult disability and 
the third leading cause of death in the world [1–4]. Cer-
ebral ischemia/reperfusion (I/R)-related injury can lead 
to brain damage, resulting in sensory and motor impair-
ment [1–3, 5]. Although brain damage resulting from 
ischemia can be devastating, many patients survive the 
initial event and experience some degree of spontaneous 
recovery, which can be further augmented by rehabilita-
tive therapy [2].
The aim of post-stroke recovery treatments is to 
enhance structural and functional reorganization (plas-
ticity) of the affected brain areas [6, 7]. Methods such 
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transcranial direct current stimulation (tDCS) have 
been identified as effective rehabilitative techniques [8, 
9]. Although the efficacy of pharmacological techniques 
for enhancing post-stroke recovery from motor and 
cognitive impairments has not been conclusively dem-
onstrated, there has been increased interest in pharma-
cotherapies that will potentially contribute to positive 
stroke rehabilitation outcomes [1]. Noradrenergic ago-
nists have been the most extensively investigated phar-
macological interventions. In animals with acquired 
brain injury, drugs that activate the noradrenergic sys-
tem improve attention, responsiveness, and other cog-
nitive skills [10]. Furthermore, medications that inhibit 
the noradrenergic system appear to have a negative 
influence on recovery. For example, administration of 
clonidine (an agonist of the α2-adrenergic receptor) 
impairs recovery of beam-walking after a sensorimo-
tor cortex lesion in the rat [11]. Similarly, simultaneous 
administration of haloperidol (a α1-adrenergic antago-
nist) reverses the therapeutic effects of noradrenergic 
stimulation [12].
The vagus nerve is a major source of afferent infor-
mation regarding visceral states, and provides input to 
the locus coeruleus (LC), which is the major source of 
norepinephrine (NE) in the brain [13, 14]. It has been 
hypothesized that release of NE contributes to the effects 
of electrical vagus nerve stimulation (VNS) on learning 
and memory, mood, seizure suppression, and recovery of 
function following brain damage. VNS increases extra-
cellular NE concentrations in both the hippocampus and 
the cortex. However, the relationship between VNS and 
cognitive function needs to be further elucidated.
Therefore, we investigated the contribution of VNS 
to the recovery of learning and memory following I/R-
related injury and the mechanisms involved in a rat 
model of occlusion and reperfusion of the middle cere-
bral artery (MCAO/R). The data demonstrate that VNS 
promotes recovery of spatial and fear memory in rats 
with ischemia-induced brain damage. We found evidence 
for the contribution of NE release induced by VNS. The 
present study contributes to the understanding of the 
effect of VNS on neuropsychiatric diseases and promotes 
discovery of novel treatments for ischemic brain injury.
Methods
Animals
Adult male Sprague–Dawley rats weighing approximately 
250 g provided by the Center of Animal Experimentation 
of Tongji Medical College, Huazhong University of Sci-
ence and Technology, China, were used in this experi-
ment. Rats were housed with food and water ad  libitum 
and a 12  h light/12  h dark cycle. Animal care was per-
formed in accordance with guidelines approved by the 
US NIH and the Wayne State University Animal Investi-
gation Committee.
Rat MCAO/R model
Rats were anesthetized with 10  % hydration chlorine 
aldehyde (0.3  mL/kg intraperitoneal injections; i.p.). 
Briefly, cerebral ischemia was produced by intra-arte-
rial filament occlusion of the left middle cerebral artery 
(MCA) for 1 h followed by reperfusion [6]. The left com-
mon carotid artery, external carotid artery (ECA), and 
internal carotid artery (ICA) were exposed. A length 
(18.5–19.5  mm) of 4–0 monofilament nylon suture (tip 
diameter 0.32–0.36  mm; Sunbio Biotech Limited Com-
pany, Beijing, China) determined by the weight of each 
rat, with its tip rounded by covering with Poly -l- lysine, 
was advanced from the ECA into the lumen of the ICA 
until it blocked the origin of the MCA. Reperfusion was 
performed by the withdrawal of the nylon suture 1 h after 
MCAO. The design of the experimental procedures is 
shown in Fig. 1.
Vagus nerve stimulation
An incision approximately 2.0 cm in length was made on 
the left ventral side of the neck just lateral to the mid-
line. The sternohyoid and sternomastoid muscles were 
separated longitudinally using small forceps and then 
retracted laterally until the carotid artery could be seen. 
The vagus nerve was then carefully separated from the 
surrounding connective tissue until a length of nerve 
sufficient for electrode placement was exposed. The left 
vagus nerve was then placed on a bipolar silver hook 
electrode, which was insulated from the surrounding tis-
sue by a piece of soft plastic sheet. The two poles of the 
electrode were 5 mm apart. The stimulation intensity was 
1 mA at a fixed frequency of 20 Hz with a 0.4 ms bipo-
lar pulse width for 3 s and a 3-s inter-train interval. The 
stimulation protocol lasted for a total of 10 min. During 
the stimulation protocol, saxol was applied to the vagus 
nerve in order to prevent it from becoming dry. Middle 
cerebral artery occlusion was then performed as pre-
viously described. After 1  h of cerebral ischemia, the 
10-min long VNS protocol was performed once more at 
the same intensity as the previous VNS. The incision area 
was then cleaned, antibiotic ointment was applied, and 
the incision was sutured. Rats were monitored until nor-
mal locomotion was observed, at which point they were 
returned to the housing room.
Lateral ventricle administration
The selective NE neurotoxin N-(2-chloroethyl)-N-ethyl-
2-bromobenzylamine-hydrochloride (DSP-4; 200 μg) was 
administered intracerebroventricularly to the left lateral 
ventricle (stereotaxic coordinates from skull surface: 
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antero-posterior: +0.9  mm; medio-lateral: +1.4  mm; 
dorso-ventral: +3.4  mm). DSP-4were dissolved in 10  % 
saline containing 0.1  % ascorbic acid and the solutions 
were infused at 1 μL/min for 6 min.
Water maze tests
The Morris water maze test was performed in a 1.25 m 
diameter circular water pool (Ethovision, Noldus Ltd, 
Wageningen, Netherlands) that was filled to a depth of 
30  cm with 25  °C tap water. The water was mixed with 
an odorless non-toxic black dye. A black 10-cm-diameter 
columnar escape platform was placed in the water, posi-
tioned 1 cm below the surface of the water. Training con-
sisted of four trials each afternoon for 5 consecutive days. 
During training, the platform was placed in a quadrant 
of the pool and the rat was placed in each of the 4 quad-
rants at the start the trial, positioned facing the wall. If 
the rat did not reach the hidden platform within 1 min, 
it was placed on the platform to rest for 30 s. The initial 
quadrant placement was consistent on each afternoon 
of testing. Latency to find the platform, path length, and 
swimming speed were measured for each rat.
Automated shuttle box test
Experiments were conducted using fully automated 
50 cm × 20 cm × 15 cm (length × height × width) shut-
tle boxes, equipped with a floor grid of 0.9-cm-diameter 
bars spaced 1.8  cm apart, and located in a sound-pro-
tected room. Loudspeakers were placed in the center of 
the ceiling above the boxes. Infrared light beams continu-
ously determined each rat’s position and if they did not 
move to the opposite end of the box before the sound 
from the loudspeaker stopped, an electric shock was 
delivered from the floor grid, thereby incentivizing them 
to complete the task. In order to minimize odor cues, the 
shuttle boxes were cleaned with 75 % ethanol after each 
testing session. Each trial started with 2 min of habitua-
tion during which the rats were allowed to freely explore 
the shuttle boxes. Habituation was followed by learn-
ing trials where a conditioned stimulus consisting of a 
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Fig. 1 The experimental protocol. a The timeline of experimental procedures. After anesthesia smoothly, DSP‑4 was administered intracerebroven‑
tricularly for 10 min after fully injected with flow rate 1 µl/min. Lateral ventricle injection time as a starting point. At 35 min, VNS was given just 
30 min before MCA occlusion, and at the 135 min, VNS was again given just after MCA reperfusion. MCA: middle cerebral artery. VNS: vagus nerve 
stimulation. b The timeline of behavioral tests
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2.4 kHz tone at 80 dB was presented for a maximum of 
10  s. Next, the unconditioned stimulus, a 1.5  mA foot 
shock, was delivered for a maximum duration of 10  s. 
The inter-trial interval was 120 s and each rat completed 
10 trials. The avoidance latency and the number of avoid-
ance conditioned responses (CRs) were recorded and 
analyzed.
Western blotting
In order to determine extracellular concentrations of NE 
following VNS and behavioral testing, rats were anesthe-
tized, sacrificed, and the hippocampus and cortical brain 
tissues were harvested. Protein extracts of samples from 
the cortex and the hippocampus were prepared in RIPA 
buffer (Beyotime Institute of Biotechnology, Nantong, 
China) using standard methods. Thirty micrograms of 
total protein per lane was resolved by 10  % SDS-PAGE 
and transferred to polyvinylidene difluoride membranes. 
Normalization was performed using dopamine beta-
hydroxylase (rabbit monoclonal; 1:1000; Epitomics Inc., 
Burlingame, CA, USA) and anti-β-actin (mouse monoclo-
nal; 1:10 000; Abcam, Cambridge, UK) antibodies. Primary 
antibodies were detected using horseradish peroxidase-
conjugated anti-rabbit or anti-mouse IgG and enhanced 
chemiluminescent reagent (ECL; Thermo-Pierce, Rock-
land, USA). Immunoreactive bands were detected using 
Kodak BioMax ML film. At least three independent repli-
cations were conducted for each experiment.
Statistical analyses
All results are presented as mean ± SD. Two-way analy-
sis of variance (ANOVA) and Bonferroni post hoc tests 
were performed for statistical comparisons between the 
groups. The two groups were compared using unpaired 
t tests. All results were considered significant at p < 0.05.
Results
Effects of VNS on spatial memory after cerebral I/R injury
Rats were trained on the Morris water maze task for 
5 d before surgery. On days 7 and 14 after surgery, ani-
mals were tested on the task to determine escape laten-
cies (time to find the platform which was always on the 
same location at any time), path length, and swimming 
speed. On the swimming trajectory plots, the white box 
represents the starting place in the water tank, the red 
line represents the swim path, and the platform is posi-
tioned at the end of the red line (Fig.  2a). During the 
training trial, escape latencies and path length gradually 
decreased. For example, on the first day of training (day-
5), the average escape latencies of the Sham, MCAO/R, 
and VNS+MCAO/R groups were 36.8, 37.7, and 37.6 s, 
respectively. However, on the fifth day of training, the 
escape latencies had decreased to 8.6, 6.4, and 8.4  s 
respectively (unpaired two-tailed t test: t(76)  =  19.04, 
p < 0.0001 for Sham group; t(35) = 15.47, p < 0.0001 for 
MCAO/R group; t(44) =  12.31, p  <  0.0001). Group dif-
ferences at any point during the training were not signifi-
cant. However, the escape latencies for the Sham group 
on days 7 and 14 after surgery were not significantly dif-
ferent from those of the later stages of training, whereas 
in the MCAO/R group, the post-surgery escape laten-
cies increased to 19.7 and 16.3  s, respectively. In the 
VNS treatment group, the escape latencies were 10.9 and 
6.6 s (escape latency was shorter on day 14 than on day 
7), both of which were significantly lower than those in 
the MCAO/R group, but not significantly different from 
those in the Sham group (Fig.  1b) [two way ANOVA: F 
(2494)  =  1.68, p  =  0.1881, Bonferroni post hoc test: 
Sham vs. MCAO/R, p < 0.001 (day 7)]. The path lengths 
exhibited a similar trend in all three groups, decreas-
ing gradually from an initial 500  cm to 200  cm at the 
end of training, without significant group differences. 
While changes in post-surgery path lengths exhibited 
a similar trend to those observed for escape latencies, 
path lengths were markedly longer on days 7 and 14 in 
the MCAO/R group (408.7 and 340.7  cm, respectively) 
than in the Sham group (156.1 and 151.4  cm, respec-
tively). The path lengths were markedly shorter in the 
VNS treatment group (205.1 and 122.9  cm, p  <  0.05) 
than in the MCAO/R group, but they were not signifi-
cantly different from those of the Sham group [Two way 
ANOVA: F (2488) = 4.11, p = 0.017. Bonferroni post hoc 
tests: Sham vs. MCAO/R, p < 0.001 (day 7), p < 0.05 (day 
14); MCAO/R vs. MCAO/R+VNS, p < 0.05 (days 7, 14) 
(Fig.  2c). Compared to pre-surgery results, there were 
no significant changes in swimming speed among any 
group [Two-way ANOVA, F (2, 150) = 6.97, p = 0.0013] 
(Fig.  2d). Thus, VNS effectively reduces spatial memory 
impairment after cerebral I/R-related injury in rats.
Effects of VNS on impaired fear memory after cerebral I/R
Changes in fear memory were examined using the shut-
tle box avoidance task on days from 5 to 16 after surgery. 
The number of electric shocks and avoidance responses 
were recorded on each testing day. The avoidance CR 
rate, mean shock duration, and latency to avoidance 
were calculated. As shown in Fig.  2, there was no ini-
tial difference in avoidance CR rates between the Sham, 
MCAO/R, and MCAO/R+VNS groups. For example, 
on post-surgery day 6, the avoidance CR rates were 20.0, 
12.3, and 20.0  %, respectively. With increased training 
over time, the avoidance CR rates increased and reached 
65.8 and 65.5  % at day 16 for the Sham and MCAO/
R+VNS groups, respectively, whereas it remained low 
at 10.6  % in the MCAO/R group [Two-way ANOVA: F 
(2465)  =  71.01, p  <  0.0001. Bonferroni post hoc tests: 
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sham vs. MCAO/R, p  <  0.05 (days 11–13), p  <  0.01 
(day 14), p  <  0.001 (days 15, 16); MCAO/R vs. MCAO/
R+VNS, p < 0.05 (days 10–11), p < 0.001 (days 12–16)] 
(Fig. 3a). The mean shock duration was negatively associ-
ated with the avoidance CR rate for all groups. The mean 
shock duration had reduced in the Sham group from the 
initial 18.9 to 6.5 s, whereas in the MCAO/R group, the 
mean shock duration was markedly longer. The mean 
shock durations for the Sham group on post-surgery 
days 5 and 16 were 45.0 and 35.5 s, respectively with no 
significant group differences. In the VNS-treated rats, 
the mean shock duration was much shorter than that of 
the MCAO/R group, but was similar to that of the Sham 
group. Moreover, the 10-s mean shock duration on post-
surgery day 16 was significantly shorter than the 22.3  s 
observed at day 5 [Two-way ANOVA, F (2315) = 165.78, 
p < 0.0001. Bonferroni post hoc tests: sham vs. MCAO/R, 
p  <  0.01 (days 3–16); MCAO/R vs. MCAO/R+VNS, 
p  <  0.05 (days 3–16)] (Fig.  3b). Avoidance latencies 
increased in the Sham group from 10.1  s on day 5 to 
25.9  s on day 16. However, the avoidance latency of the 
MCAO/R group remained short at 6.5 and 3.6 s on days 
5 and 16, respectively. The avoidance latency in the VNS 
group was between that of the Sham and MCAO/R 
groups and increased slowly from 10.0  s on day 5 to 
16.8  s on day 16 [Two-way ANOVA, F (2323) =  42.73, 
p < 0.0001. Bonferroni post hoc tests: sham vs. MCAO/R, 
p  <  0.01 (days 11–13); MCAO/R vs. MCAO/R+VNS, 
p  <  0.05 (days 14, 16)] (Fig.  3c). These results indicate 
that VNS can effectively improve memory impairment in 
fear-conditioned animals after I/R-related injury.
The effects of VNS and neurotoxin DSP‑4 on NE levels 
in cortical and hippocampal brain regions
Dopamine beta-hydroxylase (DβH), the enzyme that cat-
alyzes the conversion of dopamine to norepinephrine, is 
Fig. 2 Vagus nerve stimulation (VNS) prevents memory loss after middle cerebral artery occlusion/reperfusion (MCAO/R) injury. a Typical traces 
from a water maze experiment recorded pre‑ (day‑1) and post‑surgery (day 7 and day 14), from the Sham (n = 12), MCAO/R (n = 11), and MCAO/
R+VNS (n = 11) groups. Memory was assessed on days 7 and 14 after MCAO/R by measuring escape latencies (b), path lengths (c), and swimming 
speeds (d). *Indicates a significant difference between the MCAO/R and Sham groups. #Indicates a significant difference between the MCAO/R and 
MCAO/R+VNS groups. &Indicates a significant difference between day 7 and day 14 (p < 0.05)
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released from sympathetic neurons. Therefore, in order to 
examine the effect of VNS and DSP-4 on NE levels in the 
cortical and hippocampal brain regions, we measured the 
expression of DβH using western blotting. Figure 4 shows 
that the DβH protein was inhibited by neurotoxin DSP-4.
Damage to catecholaminergic neurons inhibited retention 
of the VNS‑mediated effect on spatial memory
The neurotoxin DSP-4, a chemical agent that damages 
noradrenergic neurons, was administered intraventricu-
larly 30  min prior to surgery. Training procedures were 
performed as previously described and swimming tra-
jectories were recorded on the Morris water maze task 
(Fig.  5a). As shown in Fig.  4, trained rats (day-1) could 
quickly locate the platform. On post-surgery day 7, the 
escape latencies of the DSP-4+MCAO/R group and the 
DSP-4+MCAO/R+VNS group were 640.3 and 416.6  s, 
respectively, which were significantly slower than the 
mean escape latency of the DSP-4+Sham group (119.5 s). 
Escape latencies did not significantly differ between the 
groups on post-surgery day 14 compared with those on 
post-surgery day 7 [Two-way ANOVA: F (2,140) = 7.61, 
p =  0.0007. Bonferroni post hoc tests: DSP-4+Sham vs. 
DSP-4+MCAO/R, p  <  0.001 (days 7, 14); DSP-4+Sham 
vs. DSP-4+MCAO/R+VNS, p  <  0.01 (day 7), p  <  0.001 
(day 14) (Fig. 5b). The swimming path length of rats in the 
DSP-4+Sham group was 63.1 cm on day-1 and 119.5 and 
90.7 cm on post-surgery days 7 and 14, respectively. The 
swimming path length of the DSP-4+MCAO/R group 
increased from 117.8 cm before surgery to 640.3 cm and 
410.27 cm on post-surgery days 7 and 14, respectively. The 
swimming path length of the DSP-4+MCAO/R+VNS 
group was similar to that of the DSP-4+MCAO/R group, 
and increased from 97.9 cm before surgery to 416.6 and 
460.8 cm on post-surgery days 7 and 14, respectively. The 
swimming path lengths of the DSP-4+MCAO/R group 
and the DSP-4+MCAO/R+VNS group on post-surgery 
days 7 and 14 were not significantly different but were 
markedly longer than those in the DSP-4+Sham group 
[Two-way ANOVA: F (2,150) = 9.84, p < 0.0001. Bonfer-
roni post hoc tests: DSP-4+Sham vs. DSP-4+MCAO/R, 
p  <  0.001 (day 7), p  <  0.01 (day 14); DSP-4+Sham vs. 
DSP-4+MCAO/R+VNS, p  <  0.01 (day 7), p  <  0.001 
(day 14)] (Fig.  5c). No changes in swimming speeds 
occurred between pre- and post-surgery testing [Two-
way ANOVA: F (2150)  =  6.97, p  <  0.0013. Bonferroni 
post hoc tests: p > 0.05.] (Fig. 5d). These results indicate 
that the previously observed protective effects of VNS on 
I/R-induced spatial memory impairment can be reversed 
by DSP-4, which damages noradrenergic neurons. Thus, 
VNS may exert its effects by increasing NE release.
Damage to catecholaminergic neurons inhibits retention 
of the VNS‑mediated effect on fear memory
Rats were treated intraventricularly with DSP-4 30  min 
before surgery and shuttle boxes were used to assess the 
Fig. 3 Vagus nerve stimulation (VNS) improves fear memory after 
middle cerebral artery occlusion and reperfusion (MCAO/R). From day 
5 to day 16 post‑surgery, rats in the Sham (n = 12), MCAO/R (n = 11), 
and MCAO/R+VNS (n = 6) groups were tested in the shuttle box and 
avoidance conditioned response rates (a), durations of shocks (b), 
and avoidance latencies were recorded (c). *,#Indicates significant 
differences (p < 0.05) between the MCAO/R and Sham groups and 
between the MCAO/R and MCAO/R+VNS groups, respectively
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number of electric shocks, mean shock duration, and 
avoidance latencies on post-surgery days 5–16. As shown 
in Fig.  5, the avoidance CR rate increased gradually 
with continued training in the DSP-4+Sham group. For 
example, the avoidance CR rate increased from 26.0  % 
on post-surgery day 6 to 76.0 % on post-surgery day 16. 
However, the avoidance CR rates did not improve with 
training in the DSP-4+MCAO/R group, yielding avoid-
ance CR rates of 18.6 % and 10.0 % at post-surgery days 
6 and 16, respectively. Moreover, the avoidance CR rates 
remained low in the DSP-4+MCAO/R+VNS group, at 
15.0 and 21.4  % on post-surgery days 6 and 16, respec-
tively [Two-way ANOVA: F (2324) =  71.01, p < 0.0001. 
Bonferroni post hoc tests: DSP-4+sham vs. DSP-
4+MCAO/R, p < 0.01 (day 8, days 13–14), p < 0.05 (day 
16)] (Fig. 6a). For the mean shock duration in the DSP-
4+Sham group, the initial rate diminished from 30.1 to 
9.9  % on post-surgery day 16. In the DSP-4+MCAO/R 
group, the mean shock durations were 54.9 and 63.5  % 
on days 6 and 16, respectively, with no significant differ-
ences between pre- and post-training rates. In the DSP-
4+MCAO/R+VNS group, the mean shock durations did 
Fig. 4 Effect of neurotoxin DSP‑4 on dopamine beta‑hydroxylase (DβH) levels after middle cerebral artery occlusion and reperfusion (MCAO/R). 
Neurotoxin DSP‑4 inhibited the DβH levels in both hippocampal (a, c) (n = 11) and cortical (b, d) (n = 3) brain regions
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not differ significantly and were 36.3 and 49.3 % on days 
6 and 16, respectively. Although the mean shock dura-
tion in the DSP-4+MCAO/R+VNS group was slightly 
lower than that in the DSP-4+MCAO/R group on post-
surgery day 16, it was substantially higher than that in the 
DSP-4+Sham group [Two-way ANOVA: F (2299) = 61, 
p  <  0.0001. Bonferroni post hoc tests: DSP-4+Sham vs. 
DSP-4+MCAO/R, p  <  0.05 (day 11), p  <  0.01 (day 8), 
p < 0.001 (days 12–16); DSP-4+Sham vs. DSP-4+MCAO/
R+VNS, p < 0.05 (days 12, 16), p < 0.01 (day 13)] (Fig. 6b). 
Avoidance latency in the DSP-4+Sham group gradually 
increased with continued training, from 10.1  % on day 
6 to 21.1  % on day 16. In contrast, no change occurred 
between pre- and post-training in the DSP-4+MCAO/R 
group, with avoidance durations of 6.8 and 4.6 % on days 
6 and 16, respectively. The avoidance latency for the DSP-
4+MCAO/R+VNS group was not significantly differ-
ent from that of the DSP-4+MCAO/R group, at 4.4 and 
8.3 % at days 6 and 16, respectively [Two-way ANOVA: 
F (2298) = 96.98, p < 0.0001. Bonferroni post hoc tests: 
DSP-4+Sham vs. DSP-4+MCAO/R, p  <  0.01 (day 12), 
p < 0.001 (days 8, 11, 13, 14, 15); DSP-4+Sham vs. DSP-
4+MCAO/R+VNS, p < 0.05 (day 16), p < 0.001 (days 8, 
11, 13, 14, 15)] (Fig. 6c). There was no difference between 
pre- and post- training values for the DSP-4+MCAO/R 
group (Fig.  6c). These results indicate that the VNS-
mediated improvement in the I/R-induced behavioral 
impairment in fear-conditioned rats can be inhibited by 
treatment with DSP-4, providing further evidence that 
NE may mediate the effects of VNS.
Discussion
VNS has been widely used clinically for treating drug-
resistant depression and refractory epilepsy. Recently, it 
was reported that VNS reduced infarct size in a rat model 
of cerebral I/R. However, the use of VNS as a treatment 
for cerebral I/R-related injury has not been thoroughly 
investigated. Using the Morris water maze and shut-
tle box behavioral tests, we found that VNS promoted 
a cognitive recovery that was reversed following the 
Fig. 5 The role of vagus nerve stimulation (VNS) in spatial memory is blocked by norepinephrine depletion. a Typical traces of water maze activity 
on day‑1, day 7, and day 14 relative to surgery were recorded from the DSP‑4+Sham (n = 7), DSP‑4+MCAO/R (n = 8), and DSP‑4+MCAO/R + VNS 
(n = 8) groups. Escape latencies (b), path lengths (c), and swimming speeds (d) were observed during training (day‑5 to day‑1) and post‑surgery 
(day 7 and day 14). *Indicates a significant difference between the DSP‑4+MCAO/R and Sham groups, while #Indicates a significant difference 
between DSP‑4+MCAO/R+VNS and DSP‑4+Sham groups. There was no difference between the DSP+MCAO/R and DSP‑4+MCAO/R+VNS groups
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administration of neurotoxin DSP-4, suggesting that the 
benefits of VNS are mediated by NE.
The afferent vagal fibers that enter the nucleus of the 
solitary tract (NTS) have widespread projections in the 
brain stem and the forebrain and subsequently project 
directly and indirectly to the LC [15]. Research find-
ings indicate that VNS activates neurons in the LC. For 
example, electrical stimulation of the vagus nerve in the 
rat increases the discharge rate of LC neurons [16]. LC 
neurons project to the hippocampus via the dorsal bun-
dle and are the main source of NE in the hippocampus 
[17]. In addition, the LC is the primary source of NE in 
the ipsilateral cortex [18]. Therefore, VNS likely exerts 
its effects by stimulating noradrenergic neurons of the 
LC to release NE on downstream targets such as the cor-
tex, hippocampus, and amygdala. In general, increasing 
the effects of NE at synapses can improve recovery from 
brain damage [19] and NE reuptake inhibitors likewise 
improve functional recovery after stroke in humans [20]. 
In contrast, NE antagonists impair recovery after a sen-
sorimotor cortex lesion in rats and may even result in a 
regression to the original, post-injury state [11]. Charac-
teristics of the animals, particularly the state of arousal, 
can modulate performance on a variety of learning and 
memory tasks including escape suppression, navigation 
through spaces, and verbal memory [2, 21]. These effects 
are attenuated by vagotomy, drugs that block arousal, or 
NTS damage. Furthermore, electrical stimulation of the 
vagus nerve improves performance on memory tasks in 
rats [22] and humans [23].
Electrical stimulation of cervical vagal afferent fibers is 
a safe and effective treatment for refractory epilepsy and 
drug-resistant depression in clinical settings [24]. It is 
also a potential treatment for migraine, senile dementia, 
traumatic brain injury, neuropathic pain, and Alzheimer’s 
disease and is currently being evaluated as such in on-
going clinical studies [24–27]. Recently, VNS has been 
reported to provide protection against cerebral ischemic 
injury in the rat [28–31]. VNS regulates several cerebral 
I/R-related pathways and inhibits cytokine synthesis, 
thereby preventing I/R-related cytokine-mediated tissue 
damage [32]. In addition, VNS is associated with reduced 
neuronal excitability [33]. In 5  min after ischemia in a 
gerbil model for VNS reduced hippocampal damage by 
50 % [34]; In a rat model of focal cerebral ischemia, VNS 
reduced infarct size [30]. Therefore, VNS is an efficacious 
neuroprotective agent against acute cerebral ischemic 
injury. VNS may improve treatment for cerebral ischemic 
damage and promote rehabilitation after injury by modu-
lating endogenous brain activity.
Fig. 6 Vagus nerve stimulation (VNS) improves fear memory after 
middle cerebral artery occlusion and reperfusion (MCAO/R). From 
day 5 to day 16 post‑surgery, rats in the DSP‑4+Sham (n = 7), DSP‑
4+MCAO/R (n = 13), and DSP‑4+MCAO/R+VNS (n = 8) groups were 
tested in shuttle boxes and the avoidance‑conditioned response 
rates (a), duration of shocks (b), and avoidance latencies were 
recorded (c). *Indicates a significant difference between the DSP‑
4+MCAO/R and Sham groups and #Indicates a significant difference 
between the DSP‑4+MCAO/R+VNS and DSP‑4+Sham groups. There 
was no difference between the DSP+MCAO/R and DSP‑4+MCAO/
R+VNS groups
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In the present surgical procedures, we selected the left 
vague nerve stimulation, which is unlikely to lead to an 
impairment in cardiovascular functioning. First, vagal 
innervation of the heart is asymmetric as there is very lit-
tle innervation of the heart by the left vagus nerve while 
the AV node is the primary region of innervation. In con-
trast, the right vagus nerve innervates the sinus node (i.e., 
the primary pacemaker) and atriums. Thus, the left VNS 
exerts little effect on heart rate. Second, when down-
stream efferent fibers are blocked by lidocaine, the influ-
ence of VNS on behavior remains. Third, NE release still 
occurs when the peripheral influence of VNS is blocked 
by atropine [35]. Therefore, this evidence indicates that 
the influence of VNS on the central nervous system is 
independent from its cardiovascular effects.
The outcome of VNS treatment is closely related to its 
specific parameter settings. Different stimulation param-
eters such as current intensity, pulse width, frequency, 
and cycle switching can induce varying types or levels of 
neurotransmitter release in different brain regions. Pre-
vious research has confirmed that a paucity of behavio-
ral changes were observed with 0.25  mA stimulation of 
the vagus nerve, but 0.5 mA and 1 mA stimulations pro-
duced simple effects on the respiratory form, such as 
changes in rhythm. Trembling or increased neck muscle 
tension was also sometimes observed with these param-
eters [36]. Previous studies also found that the inten-
sity of the electrical current used for VNS stimulation 
is closely associated with the level of NE release. VNS 
increases the concentration of NE in the hippocampus 
in a magnitude-dependent manner and the difference in 
responding to 0.5 and 1 mA VNS is substantial. However, 
in the cortex, only 1 mA VNS significantly increases the 
concentration of NE. In the cortex and hippocampus, 
VNS-induced increases in NE are transient with stimu-
lus-induced elevations and return to baseline levels in the 
inter-stimulus period [37]. The VNS-induced increase in 
NE is therapeutically beneficial. Studies have reported 
on the effects of VNS administration on depression and 
epilepsy that provide reference for selecting stimulation 
parameters. Nevertheless, systematic exploration of the 
most appropriate combination of stimulation parameters 
is important for individualized therapy, improvements in 
efficacy, the reduction of side effects, and other consider-
ations in the use of VNS. Collectively, the acute stimula-
tion parameters that were applied in our present studies 
were 1 mA intensity, 20 Hz frequency, bidirectional pulse 
with 0.4 ms pulse width, 3-s intervals after 3 s of stimula-
tion, and 10 min total stimulation for the duration of the 
protocol.
In the present study, VNS was applied 30 min before 
and after ischemia as an acute single protocol. However, 
VNS-induced improvements in cognitive functioning 
occurred from several days to several weeks after I/R-
related injury, indicating that the effects of VNS are 
more likely to initiate protective and repairing functions 
of the body rather than to maintain these functions. 
Neurons in the penumbra of cerebral I/R injury have 
two possible fates: survival or death. Effective inter-
ventions made within hours after injury are important 
prognostic factors in outcome. The time window for 
acute VNS treatment is closely related to the death or 
survival of neurons in ischemic penumbra. Therefore, 
the most likely mechanism by which acute VNS exerts 
its effect is protection. Acute VNS may also induce 
the expression and activation of neurotrophic factors 
such as brain-derived neurotrophic factor (BDNF) and 
enhance the plasticity of surviving neurons. Regard-
less, both mechanisms require further experimental 
investigation.
In order to further define the molecular mechanisms 
by which VNS improves cognitive functioning after 
ischemia, the noradrenergic neurotoxin DSP-4 was 
administered intraventricularly and the role of NE in 
cognitive functions such as spatial working memory was 
evaluated. This rat model of brain damage specifically tar-
gets noradrenergic projections originating from the LC 
and dose-dependently reduces NE levels in the brain [38]. 
Studies have shown that the release of the sympathetic 
neurotransmitter norepinephrine occurs by exocytosis 
in which the vesicular contents of the soluble protein 
DßH are also released [39] and therefore the presence of 
this protein was used to estimate the release of NE in the 
hippocampus and cortex in the present study. DSP-4 is 
an alkylating agent that forms covalent bonds with elec-
trophilic centers and is transported to the presynaptic 
membrane by high affinity interactions with the system 
that inactivates NE neurons [40]. The effects of DSP-4 are 
associated with the number of [3H] nisoxetine binding 
sites, but not the affinity for them. DSP-4 at concentra-
tions of 10, 20, 50 and l00 mg/kg can dose-dependently 
reduce cortical NE by 51, 73, and 100  %, respectively, 
while concentrations of monoamines such as 5-HT and 
dopamine do not change [38]. Therefore, in the present 
study, we used 100  mg/kg of DSP-4 to damage noradr-
energic neurons in the LC and observed the reversal of 
the therapeutic effects of VNS. Our findings indicate that 
VNS may exert its effects via NE release from noradr-
energic neurons in the LC. Intraventricular adminis-
tration of DSP-4 had no effect on cognitive behavior in 
sham-operated control rats and minimal effects on rats 
with I/R-related injury. However, there were prominent 
cognitive effects of DSP-4 in rats treated with VNS after 
I/R. DSP-4 almost completely inhibits the protective and 
restorative effects on cognitive function associated with 
VNS treatment.
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In the present study, spatial memories and fear memo-
ries were considered behavioral indicators of the func-
tional integrity of the hippocampus and cortex using the 
water maze task and automated shuttle box test, respec-
tively. VNS treatment significantly improved impair-
ments in spatial and fear memory in MCAO/R group, 
which was reversed by administration of DSP-4. Previous 
studies have shown that the hippocampus and infralim-
bic cortex are involved in memory deficits observed fol-
lowing I/R-related injury. Therefore, the results of this 
study suggest that VNS attenuates memory impairments 
following I/R-related injury by projecting neurons and 
releasing NE to the hippocampus and infralimbic cortex 
through the LC nucleus.
Inevitably, there were a few limitations to our experi-
mental design. For example, we did not include a group 
treated with VNS alone and therefore, the improved 
behavioral performance could be attributable to VNS 
itself and not the reversal of the MCAO/R effect. In addi-
tion, the timing of VNS was selected for suitability in 
possible future clinical applications. Despite these limi-
tations, the present study provides a potential treatment 
strategy for cerebral I/R-related injury.
Conclusions
VNS stimulation significantly improves spatial and fear 
memory after cerebral ischemia in rats. The therapeutic 
effects of VNS are associated with NE release. Although 
few studies have investigated VNS as a treatment follow-
ing cerebral I/R, recent findings indicate that it is a prom-
ising option. The present study also contributes to the 
understanding of the effects of VNS on neuropsychiatric 
diseases and promotes discovery of novel strategies for 
treating ischemic brain damage.
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